This is a preview of subscription content, log in via an institution to check access.
Notes
Pfizer Inc. provided financial support for conducting this investigator-initiated trial in the form of providing pegvisomant and contributing to out-of-pocket patient care costs, and was consulted on study design.
Reference
Bonert V, et al. Cost-effectiveness and efficacy of a novel combination regimen in acromegaly: a prospective, randomized trial. Journal of Clinical Endocrinology and Metabolism : 10 Jul 2020. Available from: URL: http://doi.org/10.1210/clinem/dgaa444
Rights and permissions
About this article
Cite this article
Novel combination regimen in acromegaly effective, minimises drug cost. PharmacoEcon Outcomes News 860, 24 (2020). https://doi.org/10.1007/s40274-020-7070-4
Published:
Issue Date:
DOI: https://doi.org/10.1007/s40274-020-7070-4